Inquiry Basket
CAS No.: 2306049-48-7
Cat No.: BADC-01474
4.5 
PSMA-ALB-56 is a PSMA-targeting radioligand consisting of a glutamate-urea PSMA-binding entity and an albumin conjugate.
Structure of 2306049-48-7
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
PSMA-ALB-56 is a small-molecule drug conjugate (SMDC) designed as a targeted cytotoxin for use in oncology applications. It functions as an ADC-like payload by selectively binding to the prostate-specific membrane antigen (PSMA) expressed on tumor cell surfaces. Upon internalization, PSMA-ALB-56 delivers its cytotoxic component directly to tumor cells, inducing cell cycle arrest and apoptosis through DNA damage and microtubule disruption, depending on its linked payload chemistry.
In conjugate design, PSMA-ALB-56 is linked to albumin or other carrier scaffolds via cleavable linker systems, ensuring systemic stability while enabling intracellular release in PSMA-expressing cells. The linker chemistry controls payload activation, maintaining inactivity during circulation and triggering release upon lysosomal or enzymatic processing. This targeted delivery mechanism enhances specificity to PSMA-positive tumors while limiting off-target effects.
Applications of PSMA-ALB-56 include preclinical and clinical evaluation for prostate cancer therapy and other PSMA-expressing malignancies. Its chemical structure supports diverse linker configurations and controlled intracellular payload release. PSMA-ALB-56 demonstrates defined pharmacokinetic profiles, selective internalization, and consistent cytotoxic activity in PSMA-positive cell lines, providing a mechanistically precise tool for the development of next-generation tumor-targeted conjugates.
What is PSMA-ALB-56?
PSMA-ALB-56 is a cytotoxic agent designed for conjugation in ADCs targeting prostate-specific membrane antigen (PSMA). It combines high potency with selectivity, enabling targeted preclinical research in prostate cancer models and ADC development.
29/9/2017
Dear BOC Sciences, how does PSMA-ALB-56 function in ADCs?
When conjugated to PSMA-targeting antibodies, PSMA-ALB-56 selectively enters tumor cells expressing PSMA. It induces DNA damage or inhibits essential cellular pathways, causing apoptosis and enabling evaluation of tumor-selective cytotoxicity.
10/7/2018
Dear team, what are the main applications of PSMA-ALB-56 in research?
PSMA-ALB-56 is used in preclinical ADC studies to assess payload potency, optimize linker chemistry, and evaluate tumor-selective delivery, facilitating development of prostate cancer-specific ADCs.
14/4/2019
May I ask what chemical features define PSMA-ALB-56?
PSMA-ALB-56 is a small molecule cytotoxin with functional groups enabling stable conjugation to antibodies. Its design supports selective delivery to PSMA-expressing cells while maintaining cytotoxic activity.
12/4/2020
Dear BOC Sciences, could you please advise how PSMA-ALB-56 should be handled safely?
PSMA-ALB-56 is a potent cytotoxin requiring strict lab safety, including PPE, fume hoods, and controlled waste disposal, to prevent accidental exposure during ADC synthesis and testing.
1/5/2019
— Dr. Jason Carter, Senior Scientist (USA)
PSMA-ALB-56 from BOC Sciences arrived with excellent purity, supporting our ADC research.
14/4/2019
— Dr. Kevin Scott, ADC Researcher (USA)
PSMA-ALB-56 was an excellent choice for our targeted conjugation studies. The product quality was consistent and dependable.
1/5/2019
— Ms. Elena Rossi, Molecular Scientist (Italy)
We found the PSMA-ALB-56 supplied by BOC Sciences to be highly reproducible across multiple assay types.
12/4/2020
— Mr. François Dupont, CMC Manager (France)
BOC Sciences provided PSMA-ALB-56 with complete documentation, which supported our regulatory submissions smoothly.
29/9/2017
— Dr. Mark Peterson, Biopharma Scientist (UK)
The turnaround time for PSMA-ALB-56 was fast, enabling us to stay on track with a demanding project schedule.
— Dr. Julia Weber, Oncology Research Scientist (Germany)
Our conjugation trials with PSMA-ALB-56 were successful due to its high stability and well-validated composition.
10/7/2018
PSMA-ALB-56
Required fields are marked with *
PSMA-ALB-56
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
